Lilly Endowment Inc, an insider of Eli Lilly and Co (LLY), executed a significant sale of 92,282,310 shares of the company's stock on November 24, 2025. The shares were sold at a price of $1,094.79 each, resulting in a total transaction value of approximately $101.03 billion.
Following this sale, Lilly Endowment Inc retains 92,282,310 shares of Eli Lilly and Co. Insider transactions can occur for various reasons, including diversification, tax planning, or personal financial needs. While such substantial selling activity may attract attention, it does not necessarily reflect negative sentiment towards the company.
Insider transactions are reported to the SEC, providing transparency into the actions of company executives and board members. However, investors should consider these transactions as one element among many in their analysis. Patterns of insider activity across multiple individuals and time periods can offer more insight than isolated transactions.
Eli Lilly and Co operates in the pharmaceuticals industry, focusing on the discovery, development, manufacture, and sale of pharmaceutical products. The company, headquartered in Indianapolis, Indiana, employs 47,000 full-time staff and has a market capitalization of $1,044.0 billion. It reported a P/E ratio of 56.70 and an EPS of 20.45. Upcoming earnings are projected for April 29, 2026, with an EPS estimate of $7.53 and revenue expectations of $17.5 billion.